Galderma Group AG (XSWX:GALD) Asset Impairment Charge : CHF0 Mil (TTM As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Asset Impairment Charge?

Galderma Group AG's Asset Impairment Charge for the six months ended in Jun. 2024 was CHF0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 was CHF0 Mil.

Galderma Group AG Asset Impairment Charge Historical Data

The historical data trend for Galderma Group AG's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Asset Impairment Charge Chart

Galderma Group AG Annual Data

Trend

Asset Impairment Charge

Galderma Group AG Semi-Annual Data
	Jun23	Jun24
Asset Impairment Charge	-	-

Galderma Group AG Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0 Mil.

Galderma Group AG Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (XSWX:GALD) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

GALDY:USA GDERF:USA GALDz:UK

Address

Zahlerweg 10, Zug, CHE, 6300

Website

https://www.galderma.com

Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines